Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | USP5 | P45974 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10021098 | 0.84 | RIPK1 (0.58) | RIPK1CYP2C9HIF1AKDM4ESMN1; SMN2 | |
| SCHEMBL12928765 | 0.82 | RIPK1 (0.85) | RIPK1KDM4EAOC3 | |
| SCHEMBL9081551 | 0.79 | SMN1; SMN2 (0.39) | RIPK1CYP2C9HIF1AKDM4ENPC1 | |
| SCHEMBL6055426 | 0.79 | KDM4E (0.44) | RIPK1KDM4ENPC1POLBRAB9A | |
| SCHEMBL23900841 | 0.78 | RIPK1 (0.67) | RIPK1HIF1AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL317277 | 0.78 | RIPK1 (0.56) | RIPK1 | |
| SCHEMBL22390594 | 0.78 | RIPK1 (0.67) | RIPK1HIF1AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22389480 | 0.78 | RIPK1 (0.67) | RIPK1HIF1AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13232166 | 0.78 | S1PR2 (0.46) | KDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6055300 | 0.77 | LMNA (0.41) | RIPK1KDM4ENPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8362054-B2 | Therapeutic substituted lactams | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100168189-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7713968-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090270387-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | RIPK1 4834/4885CYP2D6 18/4885CYP2C9 260/4885 |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | RIPK1 4834/4885CYP2D6 18/4885CYP2C9 260/4885 |
| US-20090270387-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, UGT2B7, GBA1 | RIPK1 4860/4885CYP2D6 15/4885CYP2C9 139/4885 |
| US-20100168189-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | PIGO, GARS1, CLPP | RIPK1 3889/4885CYP2D6 632/4885CYP2C9 696/4885 |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | RIPK1 4840/4885CYP2D6 12/4885CYP2C9 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.